OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
JYNT$8.2158

Joint Corp

Healthcare Facilities & ServicesVerified

Joint Corp maintains a strong liquidity position, with $17.46 million in cash and equivalents, representing 21.2% of total assets. The company's price-to-book ratio of 5.05 suggests a premium valuation relative to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset discounting. The company's liquidity risk is assessed as low, with no immediate filing-based liquidity flags detected. Profitability metrics show a challenging performance, with a negative return on equity of -15.51% and a return on assets of -4.36%, both significantly below industry norms. Operating income is negative at -$1.78 million, and net income is -$3.60 million, indicating operational inefficiencies or high costs relative to revenue. Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue is concentrated in a single business line, as no segment breakdown is provided. This lack of diversification may increase exposure to sector-specific risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. Analysts have assigned a mean price target of $10.00, suggesting a potential upside from the current market price of $8.21. However, the absence of positive earnings and the negative operating cash flow of $1.84 million raise concerns about long-term growth sustainability. Risk factors include the company's negative net income and operating income, which could impact its ability to service debt or fund operations without external financing. The dilution risk is assessed as low, with no immediate filing-based dilution flags detected. However, the company's free cash flow is negative at -$448,610, which may necessitate future capital raises. Recent events include the publication of the latest financial data, which shows a revenue of $12.61 million and a gross profit of $9.80 million. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.

30-day price · JYNT-0.17 (-1.9%)
Low$8.50High$9.43Close$8.68As of13 May, 00:00 UTC
Profile
CompanyJoint Corp
TickerJYNT.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Joint Corp operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Joint Corp maintains a strong liquidity position, with $17.46 million in cash and equivalents, representing 21.2% of total assets. The company's price-to-book ratio of 5.05 suggests a premium valuation relative to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset discounting. The company's liquidity risk is assessed as low, with no immediate filing-based liquidity flags detected. Profitability metrics show a challenging performance, with a negative return on equity of -15.51% and a return on assets of -4.36%, both significantly below industry norms. Operating income is negative at -$1.78 million, and net income is -$3.60 million, indicating operational inefficiencies or high costs relative to revenue. Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue is concentrated in a single business line, as no segment breakdown is provided. This lack of diversification may increase exposure to sector-specific risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. Analysts have assigned a mean price target of $10.00, suggesting a potential upside from the current market price of $8.21. However, the absence of positive earnings and the negative operating cash flow of $1.84 million raise concerns about long-term growth sustainability. Risk factors include the company's negative net income and operating income, which could impact its ability to service debt or fund operations without external financing. The dilution risk is assessed as low, with no immediate filing-based dilution flags detected. However, the company's free cash flow is negative at -$448,610, which may necessitate future capital raises. Recent events include the publication of the latest financial data, which shows a revenue of $12.61 million and a gross profit of $9.80 million. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.
Key takeaways
  • Joint Corp has a strong liquidity position with $17.46 million in cash and equivalents.
  • The company's profitability is weak, with a negative return on equity and return on assets.
  • Analysts have a cautiously optimistic outlook, with a mean price target of $10.00.
  • The company's free cash flow is negative, indicating potential future capital needs.
  • No immediate liquidity or dilution risks have been identified.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$12.6M
Gross profit$9.8M
Operating income-$1.8M
Net income-$3.6M
R&D
SG&A
D&A
SBC
Operating cash flow$1.8M
CapEx-$657.5k
Free cash flow-$448.6k
Total assets$82.4M
Total liabilities$59.3M
Total equity$23.2M
Cash & equivalents$17.5M
Long-term debt$50.9k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$80.0M$6.1M$7.6M$4.5M
FY-3$101.3M$828.2k$626.7k$1.4M
FY-2$47.0M$318.3k-$9.8M-$14.5M
FY-1$52.2M-$1.9M-$5.8M$1.9M
FY0$54.9M-$913.4k$2.9M-$58.2k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$87.1M$30.3M$19.5M
FY-3$93.5M$32.6M$9.7M
FY-2$87.2M$24.7M$18.2M
FY-1$83.2M$20.7M$25.1M
FY0$61.0M$15.1M$23.6M
PeriodOCFCapExFCFSBC
FY-4$13.8M-$7.0M$4.5M
FY-3$8.2M-$5.9M$1.4M
FY-2$14.7M-$5.0M-$14.5M
FY-1$9.4M-$1.2M$1.9M
FY0$1.8M-$1.5M-$58.2k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$12.6M-$1.8M-$3.6M-$448.6k
FQ-6$12.7M-$492.8k-$3.2M$580.9k
FQ-5$14.7M$809.7k$17.7k$1.2M
FQ-4$13.1M-$678.5k$801.4k-$437.5k
FQ-3$13.3M-$1.1M$93.4k-$1.1M
FQ-2$13.4M$160.9k$855.0k$435.6k
FQ-1$15.2M$742.4k$991.1k$1.0M
FQ0$14.8M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$82.4M$23.2M$17.5M
FQ-6$79.6M$20.5M$20.7M
FQ-5$83.2M$20.7M$25.1M
FQ-4$77.2M$19.9M$21.9M
FQ-3$73.2M$23.2M$29.8M
FQ-2$69.4M$22.7M$29.7M
FQ-1$61.0M$15.1M$23.6M
FQ0$15.5M$20.7M
PeriodOCFCapExFCFSBC
FQ-7$1.8M-$657.5k-$448.6k
FQ-6$5.3M-$901.4k$580.9k
FQ-5$9.4M-$1.2M$1.2M
FQ-4-$3.7M-$331.5k-$437.5k
FQ-3-$2.8M-$836.5k-$1.1M
FQ-2-$1.1M-$1.2M$435.6k
FQ-1$1.8M-$1.5M$1.0M
FQ0-$1.5M-$234.6k
Valuation
Market price$8.21
Market cap$117.0M
Enterprise value$99.6M
P/E
Reported non-GAAP P/E
EV/Revenue7.9
EV/Op income
EV/OCF54.2
P/B5.0
P/Tangible book5.0
Tangible book$23.2M
Net cash$17.4M
Current ratio1.3
Debt/Equity0.0
ROA-4.4%
ROE-15.5%
Cash conversion-51.0%
CapEx/Revenue-5.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricJYNTActivity
Op margin-14.1%5.6% medp25 -4.2% · p75 12.6%bottom quartile
Net margin-28.5%2.8% medp25 -3.4% · p75 8.8%bottom quartile
Gross margin77.7%36.5% medp25 23.7% · p75 65.2%top quartile
CapEx / revenue-5.2%-4.9% medp25 -11.5% · p75 -2.0%below median
Debt / equity0.0%69.3% medp25 7.9% · p75 120.9%bottom quartile
Recent coverage
Observations
IR observations
Mean price target10.00 USD
Median price target9.00 USD
High price target12.00 USD
Low price target9.00 USD
Mean recommendation2.75 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count3.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.25 USD
Last actual EPS0.19 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 16:40 UTC#04e219c1
Market quoteclose USD 8.69 · shares 0.01B diluted
no public URL
2026-05-16 16:41 UTC#24c4ac8a
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 07:09 UTCJob: 52519a47